drugset / Trial / NCT05485584
rSIFN-co Among Healthy Subjects and Subjects With Mild or Asymptomatic COVID-19
RandomizedParallel-groupSingle-blindPrevention
Summary
This is a phase II pilot, international, multicenter, randomized, double-blind, placebo-controlled study that aims to evaluate the safety and preliminary efficacy of rSIFN-co nasal spray in healthy subjects in close contact with confirmed COVID-19 case(s) as well as subjects with mild or asymptomatic COVID-19.
Timeline
- Start
- 2022-07-01
- Primary completion
- 2023-04-05
- Completion
- 2023-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Interferon Alfacon-1 | Protein / enzyme biologic | 8e+06 iu | Intranasal |
| Subject | Interferon Alfacon-1 | Protein / enzyme biologic | 1.6e+07 iu | Intranasal |